Table 3.
Univariate analyses for the development of grade II–IV and III–IV aGVHD and multivariate analysis for the development of grade II–IV aGVHD
| Patient and Graft Characteristics | Univariate analysis Grade II–IV aGVHD | Univariate analysis Grade III–IV aGVHD | Multivariate analysis Grade II–IV aGVHD | |||
|---|---|---|---|---|---|---|
|
| ||||||
| Hazard Ratioa | P value | Hazard Ratioa | P value | Hazard Ratioa | P value | |
|
| ||||||
| Gender | ||||||
| Male (n = 134) | Reference | 0.654 | Reference | 0.340 | - | - |
| Female (n = 107) | 0.9 (0.5–1.6) | 0.6 (0.2–1.8) | ||||
|
| ||||||
| Age (years)b | ||||||
| < 56.7 (n =120 ) | Reference | 0.631 | Reference | 0.409 | - | - |
| ≥ 56.7 (n =121 ) | 0.9 (0.5–1.6) | 0.6 (0.2–1.9) | ||||
|
| ||||||
| Recipient CMV | ||||||
| Seronegative (n = 105) | Reference | 0.563 | Reference | 0.028 | Reference | 0.665 |
| Seropositive (n = 136) | 0.8 (0.4–1.6) | 0.2 (0.1–0.9) | 0.9 (0.5–1.6) | |||
|
| ||||||
| Donor | ||||||
| Related (n = 93) | Reference | 0.436 | Reference | 0.962 | - | - |
| Unrelated (n = 148) | 1.3 (0.7–2.5) | 1.0 (0.3–3.1) | ||||
|
| ||||||
| HCT-CI | ||||||
| 0 (n = 41) | Reference | Reference | 0.848 | |||
| 1–2 (n = 88) | 1.2 (0.4–3.0) | 0.870 | 0.6 (0.1–2.9) | - | - | |
| ≥ 3 (n = 112) | 1.3 (0.5–3.2) | 0.8 (0.2–3.2) | ||||
|
| ||||||
| Conditioning regimen | ||||||
| Chemotherapy (n = 158) | Reference | 0.572 | Reference | 0.125 | - | - |
| TBI (n = 83) | 1.2 (0.6–2.3) | 2.3 (0.8–7.0) | ||||
|
| ||||||
| CD3+ × 103/kg dose* | ||||||
| < 2.2 (n = 117) | Reference | 0.201 | Reference | 0.601 | - | - |
| > 2.2 (n = 120 | 1.5 (0.8–2.9) | 1.4 (0.4–4.3) | ||||
|
| ||||||
| CD34+ × 106/kg dose** | ||||||
| < 7.74 (n = 119) | Reference | 0.264 | Reference | 0.979 | - | - |
| ≥ 7.74 (n = 120) | 0.7 (0.4–1.3) | 1.0 (0.3–3.1) | ||||
|
| ||||||
| Donor-recipient HLA-match | ||||||
| 8/8 (n = 200) | Reference | 0.322 | Reference | 0.196 | Reference | 0.173 |
| 7/8 (n = 41) | 1.5 (0.7–3.1) | 2.2 (0.7–7.1) | 1.7 (0.5–3.6) | |||
|
| ||||||
| TCD method | ||||||
| CliniMACS (n = 171) | Reference | 0.050 | Reference | 0.850 | Ref. | 0.038 |
| Isolex (n = 70) | 0.4 (0.2–1.0) | 1.1 (0.3–3.6) | 0.4 (0.2–0.9) | |||
a
includes 95% confidence interval.
b
Age cut-off based on the median.
aGVHD indicates acute graft-versus-host disease; CMV, cytomegalovirus; HLA, human-leukocyte antigen; TNC, total nucleated cell; kg, kilogram.
*
Data missing in 4 patients,
**
data missing in 2 patients.